Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WIZ | O95785 | 2/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841367 | 1.00 | WIZ (0.52) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL31047983 | 1.00 | WIZ (0.52) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL27314508 | 0.92 | CRBN (0.55) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL20046362 | 0.89 | CRBN (0.59) | WIZIKZF1CRBNIKZF2 | |
| SCHEMBL29841418 | 0.88 | IKZF2 (0.55) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL24735214 | 0.88 | IKZF2 (0.55) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL24735004 | 0.88 | IKZF2 (0.55) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL21340262 | 0.88 | IKZF1 (0.68) | IKZF1IKZF2 | |
| SCHEMBL24206987 | 0.86 | CRBN (0.54) | WIZIKZF1CRBNIKZF3IKZF2 | |
| SCHEMBL31047975 | 0.86 | CRBN (0.48) | WIZIKZF1CRBNIKZF3IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | WIZ 3555/4885IKZF1 329/4885CRBN 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.